Table 2 Trial characteristics

From: Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

 

No. of trials

%

No. of patients

%

Number of MTAs

 Single agent

13

72

42

84

 Combination

5

28

8

16

Trial phase

 Phase I

3

17

16

32

 Phase I/II

2

11

2

4

 Phase II

12

67

28

56

 Phase III

1

6

4

8

Targets of MTAs a

 HER-2

5

22

7

13

 VEGFR

4

17

7

13

 EGFR/HER-2

4

17

11

21

 IGF-1R

3

13

7

13

 EGFR

1

4

1

2

 mTOR

1

4

1

2

 CDK

1

4

3

6

 SRC

1

4

2

4

 HDAC

1

4

1

2

 PKC

1

4

4

8

 MEK

1

4

9

17

  1. Abbreviation: MTA=molecularly targeted agent.
  2. aThe number of MTAs is superior to the number of trials as five of the trials are combination trials.
Back to article page